This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Lorvotuzumab mertansine, huN901-DM1, BB-10901, maytansinoid-conjugated humanised monoclonal antibody
Description: HuN901-DM1 consists of a CD56-binding monoclonalantibody, huN901, with a maytansinoid agent, DM1, attached via a stabledisulfide linker, SPP.
Deal Structure: In May 2000 ImmunoGen licensed to British Biotech the rights to develop and commercialize huN901-DM1 for Europe and Japan; British Biotech also was responsible for developing the product for marketing approval in the U.S.
In 2003, British Biotech merged with RiboTargets, Ltd. and the combined entity subsequently merged with Vernalis Group plc to become Vernalis plc. As a result of these changes, ImmunoGen and Vernalis renegotiated their agreement on huN901-DM1. ImmunoGen agreed to take over future development of the compound.
Vernalis, which agreed to relinquish its rights to the product, agreed to complete the U.K. Phase I clinical study of huN901-DM1 and agreed to continue the U.S. Phase I/II study until June 30, 2004. If the U.S. Phase I/II study is not completed as of that date, ImmunoGen agreed to assume responsibility for it.
Additional information available to subscribers only: